Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension

J Med Chem. 2016 Sep 8;59(17):7901-14. doi: 10.1021/acs.jmedchem.6b00703.

Duncan E Shaw ¹, Ferheen Baig, Ian Bruce, Sylvie Chamoin ², Stephen P Collingwood, Sarah Cross ¹, Satish Dayal, Peter Drückes ², Pascal Furet ², Vikki Furminger, Deborah Haggart ³, Martin Hussey, Irena Konstantinova, Jon C Loren ³, Valentina Molteni ³, Sonia Roberts, John Reilly, Alex M Saunders, Rowan Stringer, Lilya Sviridenko, Matthew Thomas, Christopher G Thomson ¹, Christine Tomlins, Ben Wen ³, Vince Yeh ³, Andrew C Pearce

Affiliations

1 Novartis Institutes of Biomedical Research (NIBR) , 100 Technology Square, Cambridge, Massachusetts 02139, United States.
2 NIBR , Basel Fabrikstrasse 2, 4056 Basel, Switzerland.
3 Genomics Institute of the Novartis Research Foundation , 10675 John Jay Hopkins Drive, San Diego, California 92121, United States.

PMID: 27502700 DOI: 10.1021/acs.jmedchem.6b00703

Abstract

A series of potent PDGFR inhibitors has been identified. The series was optimized for duration of action in the lung. A novel kinase occupancy assay was used to directly measure target occupancy after i.t. dosing. Compound 25 shows 24 h occupancy of the PDGFR kinase domain, after a single i.t. dose and has efficacy at 0.03 mg/kg, in the rat moncrotaline model of pulmonary arterial hypertension. Examination of PK/PD data from the optimization effort has revealed in vitro:in vivo correlations which link duration of action in vivo with low permeability and high basicity and demonstrate that nonspecific binding to lung tissue increases with lipophilicity.

Name
Email *

	Sorry, but the email address you supplied was invalid.